Title : The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.

Pub. Date : 2015 May 8

PMID : 25952930






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Sorafenib and everolimus combination was effective in mTOR and ERM blockade; exerted synergistic effects on the inhibition of MPM cell proliferation; triggered ROS production and consequent AMPK-p38 mediated-apoptosis. Sorafenib mechanistic target of rapamycin kinase Mus musculus
2 CONCLUSIONS: ERM and mTOR pathways are activated in MPM and "druggable" by a combination of sorafenib and everolimus. Sorafenib mechanistic target of rapamycin kinase Mus musculus